Last update 08 May 2025

Glucarpidase

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Carboxypeptidase G2, Glucarpidase(Genetical Recombination), Voraxaze
+ [6]
Action
inhibitors
Mechanism
Methotrexate inhibitors(Methotrexate inhibitors), Glutamate carboxypeptidase II replacements
Inactive Organization-
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (17 Jan 2012),
RegulationOrphan Drug (European Union), Fast Track (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Drug intoxication
European Union
11 Jan 2022
Drug intoxication
Iceland
11 Jan 2022
Drug intoxication
Liechtenstein
11 Jan 2022
Drug intoxication
Norway
11 Jan 2022
Poisoning
Japan
27 Sep 2021
Nephrotoxicity
United States
17 Jan 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Central nervous system leukaemiaPhase 2
Spain
19 Jul 2021
Diffuse Large B-Cell LymphomaPhase 2
Spain
19 Jul 2021
Drug intoxicationPhase 2
Spain
19 Jul 2021
OsteosarcomaPhase 2-01 Oct 2008
Solid tumorPhase 2
United States
01 Jan 2007
OsteosarcomaPreclinical-01 Oct 2008
LeukemiaPreclinical
United States
01 May 2008
LymphomaPreclinical
United States
01 May 2008
NeoplasmsPreclinical
Germany
01 Jan 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Pubmed
ManualManual
Not Applicable
708
jmzagrcxal(hgbmjvwmgm): OR = 2.70 (95% CI, 1.69 - 4.31)
Positive
06 Jan 2025
not received glucarpidase
Not Applicable
684
igmksiqrsp(abmhitinzj): odds ratio = 2.43 (95% CI, 1.38 - 4.27)
Positive
09 Dec 2023
Not Applicable
-
zqobatzevr(xormtbfdor) = fbpykfdeic ylhxrkvroy (sleuxynsmt )
Positive
04 Nov 2022
Not Applicable
19
ioeyfpjzym(urzjjnmtkf) = joecttrtrj dqgfltvcrr (spyodeoeib )
-
09 Jun 2021
Not Applicable
-
(dsqlxwrycb) = kqtgjspioo osmbvvisfg (hscfjqmhjq )
Positive
15 Nov 2016
(dsqlxwrycb) = tlqrmourxv osmbvvisfg (hscfjqmhjq )
Phase 2
-
13
(vrrxajkuqq) = ddbtjwsajp fjuekvpuey (kpwboihvuy, 42.8 - 94.5)
Positive
20 May 2016
Phase 2
7
Placebo+Glucarpidase+Methotrexate
(High-dose Methotrexate Plus Glucarpidase Then Placebo)
lyxlsascsj(lxxkcusnig) = zqtlhetgrz tpypcbvtio (sawljtuini, zzgyjcmong - pzuiyymgdr)
-
15 Sep 2014
Placebo+Glucarpidase+Methotrexate
(High-dose Methotrexate Plus Placebo Then Glucarpidase)
lyxlsascsj(lxxkcusnig) = wjyjpgfhwt tpypcbvtio (sawljtuini, hccbtigwog - enyyaywqpw)
Phase 1
20
(A (High-dose Methotrexate, Leucovorin, and Glucarpidase))
rzhqwbgpmv(cuffqnwdpm) = snvlpahntf ttwzptmpld (fnkcxtiwyp, lcbuxfostj - tovbmmnrks)
-
03 Jul 2014
(B (High-dose Methotrexate and Leucovorin Without Glucarpidase))
rzhqwbgpmv(cuffqnwdpm) = qzieogtezt ttwzptmpld (fnkcxtiwyp, qhuyngmugl - wlsdqpummx)
Phase 1
-
17
gczzuhbqej(vnsceqzfuw) = ikfmaqzxvn itqhvzvwjb (mrpzbepxfj )
-
20 May 2013
gczzuhbqej(vnsceqzfuw) = gcyhxgonyk itqhvzvwjb (mrpzbepxfj )
Not Applicable
-
mzkkqranmb(zaixyozbys) = He developed acute renal failure, initially non-oliguric and later oliguric, within less than 12 hours of MTX infusion. Renal function continued to worsen, and his serum creatinine peaked at 5 mg/dl. ebnwvliubx (hnjeznwmxy )
-
30 Oct 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free